XFLH Capital Corporation filed a Form 8-K with the SEC on September 22, 2026, disclosing that it entered into a letter of intent on September 18, 2026, with Renogen Biolab Inc. for a proposed business combination.
Key Highlights
- Letter of Intent signed: XFLH Capital Corporation and Renogen Biolab Inc. entered into a letter of intent on September 18, 2026, for a proposed business combination.
- Target company profile: Renogen Biolab Inc. is described in the filing as a Canadian corporation and health service provider offering molecular capabilities including DNA services, vector engineering, and protein expression.
- Next steps outlined: According to the filing, both parties agreed to use their "reasonable best efforts to act in good faith to negotiate the definitive agreements" as soon as possible.
- Due diligence access: The filing states both parties agreed to provide reasonable access to information for the purpose of conducting a due diligence inquiry.
- Press release issued: On September 22, 2026, the company issued a press release announcing the signing of the letter of intent.
- Proxy statement anticipated: The filing notes that if a definitive agreement is entered into, the company will prepare a proxy statement to be filed with the SEC and mailed to stockholders.
XFLH Capital's Proposed Combination With Renogen Biolab: What the Filing Discloses
According to the Form 8-K filed by XFLH Capital Corporation (NYSE:XFLH), the company entered into a letter of intent with Renogen Biolab Inc. on September 18, 2026. The filing describes Renogen Biolab as "a Canadian corporation and a health service provider that offers and provides several core molecular capabilities including DNA services, vector engineering, and protein expression." The letter of intent covers a proposed business combination between the two parties, though no definitive agreement has been executed.
The filing states that pursuant to the letter of intent, both parties have agreed to use their "reasonable best efforts to act in good faith to negotiate the definitive agreements embodying the Proposed Business Combination as soon as possible." The company also confirmed that both parties would provide each other with "reasonable access to information for the purpose of conducting a due diligence inquiry." No financial terms of the proposed transaction are disclosed in the filing.
The filing includes forward-looking statements, which the company identifies as subject to "risks, uncertainties, and assumptions that are difficult to predict." The company explicitly notes that actual results could differ materially, citing factors including "the ability of the parties to enter into a definitive agreement and satisfy the closing conditions" and "competitive factors in the Company's and Renogen Biolab's industry and market." The filing was signed by Yanzhe Yang, Chief Executive Officer of XFLH Capital Corporation, dated September 22, 2026.
What Was Disclosed
XFLH Capital Corporation disclosed the signing of a letter of intent with Renogen Biolab Inc. for a proposed business combination. No definitive agreement has been reached, and no financial terms were included in the filing.






Please wait processing your request...